J Drugs Dermatol. 2021 Feb 1;20(2):208-214. doi: 10.36849/JDD.4931.
Psoriasis is an immunomediated disease mostly controlled at the outpatient level, although there is a low percentage of patients that require systemic drugs or even hospitalization for an adequate control. Biological drugs have represented a turning point in its treatment. So far, despite the growing interest in psoriasis and its management with biological therapies, there is a lack of studies focusing on their impact on hospitalization, a relevant issue to patients and to the sustainability of our healthcare system.
In this study, we aimed to describe the temporal evolution of the hospitalizations of patients with psoriasis throughout the period between eight years before the commercialization of the first biological drugs and present, and secondly, whether this market irruption was related to a decrease in the number of admissions.
Data was collected retrospectively from the Dermatology department of the Complexo Hospitalario Universitario de Ponte- vedra (CHUP) including patients of all ages with a diagnosis of psoriasis and at least one admission to the department of Dermatology along the study period. We established different time periods for comparing the average hospitalizations per 100,000 inhabitants-year and the average stay, considering that the first biologic drug marketed for the treatment of psoriasis was in 2004.
Regression models indicated a significant change in the temporal trend of the hospitalization rate per 100,000 inhabitants-year starting in 2004. In all cases, a gradual and significant decrease in the number of admissions per 100,000 inhabitants-year and in the average hospitalization rate per psoriasis per 100,000 inhabitants-year along the study period were found. There was also a significant decrease in medical hospitalizations and medical hospitalizations excluding psoriasis throughout the study period.
In our study population hospitalizations for psoriasis descended progressively and significantly from 2004. So far there are no extensive data on the impact of biological therapies on psoriasis hospitalization. J Drugs Dermatol. 2021;20(2):208-214. doi:10.36849/JDD.4931.
银屑病是一种免疫介导的疾病，大多在门诊水平得到控制，尽管有一小部分患者需要系统药物治疗，甚至需要住院才能得到充分控制。生物药物的出现代表了治疗的一个转折点。迄今为止，尽管人们对银屑病及其生物治疗越来越感兴趣，但缺乏专门研究生物治疗对住院治疗影响的研究，这是一个与患者和我们医疗体系可持续性相关的重要问题。
本研究旨在描述银屑病患者住院治疗的时间演变，从第一个生物药物上市前八年到现在，并其次，这种市场冲击是否与住院人数减少有关。
从蓬特韦德拉综合医院皮肤科（CHUP）收集了所有年龄段的银屑病患者的数据，这些患者在研究期间至少有一次因银屑病入住皮肤科。我们为比较每 10 万居民年的平均住院人数和平均住院时间设立了不同的时间段，考虑到第一个用于治疗银屑病的生物药物于 2004 年上市。
回归模型表明，从 2004 年开始，每 10 万居民年的住院率时间趋势发生了显著变化。在所有情况下，都发现了每 10 万居民年的住院人数和每 10 万居民年的银屑病平均住院率逐年逐渐显著减少。整个研究期间，医疗住院和排除银屑病的医疗住院也显著减少。
在我们的研究人群中，银屑病的住院率从 2004 年开始逐渐显著下降。到目前为止，关于生物疗法对银屑病住院治疗影响的广泛数据还没有。J 皮肤病药物杂志。2021;20(2):208-214. doi:10.36849/JDD.4931.
